Viehbacher (Sanofi), Russell (Shire), Scangos (Biogen) and other CEOs say the Big Pharma big brand, blockbuster drug model is done! Time to get out the forks.
Now the trend is toward developing products aimed at specialty markets -- like rare diseases, including genetic diseases. Sanofi just acquired Genzyme for that reason. Shire also focuses its development efforts in this area and has double digit growth rates and a high P/E multiple to show for it.
Now Big Pharma wants to play too. Which is great, except if everyone is after a rare disease model is it rare any longer? Being a copycat is the sincerest form of flattery until all the profits are gone.
Posted by Bruce Lehr May 16th 2011.